CO6 Teduglutide for Treating Short-Bowel Syndrome in Adults: A Meta-Analysis of Real-World Evidence Compared to Clinical Trial Data
Teduglutide is a treatment that allows patients with short bowel syndrome and type 3 intestinal failure (SBS- IF) to reduce their dependence on intravenous nutrition and fluids (parenteral support; PS). A pivotal randomized controlled trial (RCT) of teduglutide showed 63% of patients experienced a ≥20% reduction in weekly PS volume at 24 weeks. Individual real-world evidence (RWE) studies have reported greater and more rapid PS reductions than clinical trials, but whether this is a general trend is unknown.
Source: Value in Health - Category: International Medicine & Public Health Authors: J. Eaton, R. Harvey, P. Cain, A. Dallongeville, S. Campbell-Hill Source Type: research
More News: Clinical Trials | International Medicine & Public Health | Nutrition | Parenteral Nutrition | Study